Abiopharma

🔍 QVT Financial LP (Executive)

Company: Roivant Sciences Ltd. (ROIV)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Sold 300,783 shares of Common Shares at $33.92 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: false | shares_owned_after: 14,826,546.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 325,000 shares of Common Shares at $34.07 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: false | shares_owned_after: 14,501,546.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 200,000 shares of Common Shares at $34.44 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: false | shares_owned_after: 14,301,546.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 600,000 shares of Common Shares at $34.59 per share (Direct)
  Date: 2026-06-29 | Code: S | equity_swap_involved: false | shares_owned_after: 13,701,546.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12,380 shares of Common Shares at $35.28 per share (Direct)
  Date: 2026-06-30 | Code: S | equity_swap_involved: false | shares_owned_after: 13,689,166.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT FIC. QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
• F2: QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.